The GLP is committed to full transparency. Download and review our 2019 Annual Report

Drug cocktail shows promise against pancreatic cancer, highlighting potential of combined treatments

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Researchers led by a team at Sanford Burnham Prebys Medical Discovery Institute have identified a combination of two already approved anticancer compounds that can significantly shrink pancreatic tumors and melanoma tumors in mice.

For their study, the scientists first used a drug called L-asparaginase (L-Aase) to starve pancreatic tumors of asparagine (L-Asn). However, they found that instead of dying, the tumor turned on the MAPK stress response pathway that allowed the cancer cells to produce asparagine from scratch. The scientists then treated mice with a second drug, an MEK inhibitor (MEKi), which blocked the stress response pathway. This dual approach effectively shrank the pancreatic tumors. L-asparaginase is already approved by the FDA to treat certain leukemias, and the MEK inhibitor is approved for the treatment of solid tumors, including melanoma.

Related article:  How our bodies protect cancer and why this could be key to better chemotherapy treatments

Rosalie C. Sears, PhD, a professor at Oregon Health & Science University, added: “It’s clear we’re not going to find a single magic bullet that cures cancer but will instead need several drugs that target multiple vulnerabilities. This study identifies a promising dual treatment for pancreatic cancer—one of the deadliest cancers—and I look forward to seeing these drugs tested in patients.”

Read full, original post: Pancreatic Tumors Succumb to Combination of Two Approved Drugs

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend